From GlobeNewswire: 2025-05-12 08:00:00

FDA meeting for Tanruprubart (ANX005), the first potential targeted therapy for GBS, scheduled for second quarter 2025 before BLA submission. Open-label Tanruprubart FORWARD study to broaden patient experience in North America and Europe starting in second quarter 2025. Phase 3 ARCHER II trial for ANX007 on track for completion in third quarter 2025, with pivotal data expected in second half of 2026. Proof-of-concept trial for ANX1502 in Cold Agglutin Disease expected mid-2025, aiming to disrupt current treatment for autoimmune diseases. $263.7 million in cash, cash equivalents, and short-term investments as of March 31, 2025, to fund late-stage milestones for lead programs into second half of 2026.

Annexon, Inc. is advancing late-stage clinical therapies for complement-mediated neuroinflammatory diseases. Tanruprubart for GBS approaching BLA submission after positive trial results. ANX007 for Dry AMD in Phase 3 trial with enrollment on track. ANX1502 in trial for autoimmune conditions. Financially stable with $263.7 million in cash as of March 31, 2025. Mission to help patients live their best lives.

Tanruprubart (ANX005) aims to be the first targeted therapy for GBS, a rare neuromuscular emergency. Positive results in clinical studies highlight its therapeutic potential. FDA meeting scheduled for second quarter 2025. Open-label FORWARD study to provide patient and physician experience in North America and Europe. Phase 3 ARCHER II trial for ANX007 progressing, with topline data expected in 2026.

ANX007 targets Dry AMD with GA, a leading cause of blindness. Phase 3 ARCHER II trial enrollment to be completed in third quarter 2025. ANX1502, a first-of-its-kind oral inhibitor for autoimmune conditions, in proof-of-concept trial. Financially stable with $263.7 million in cash as of March 31, 2025. Focus on delivering innovative therapies for neuroinflammatory diseases.

Annexon Biosciences is developing novel treatments to stop neuroinflammation in serious diseases. Their C1q-focused approach aims to prevent tissue damage in autoimmune, neurodegenerative, and ophthalmic conditions. Pipeline includes ANX005 for GBS, ANX007 for Dry AMD, and ANX1502 for autoimmune diseases. Financially stable with $263.7 million in cash as of March 31, 2025. Mission to provide game-changing therapies for patients.



Read more at GlobeNewswire:: Annexon Reports First Quarter 2025 Financial Results,